Researchers at the Free University of Brussels have discovered that healthy pancreatic tissue harbors rare cells that already possess the hallmark properties of aggressive cancer—a finding that could fundamentally change how doctors approach early detection and treatment of one of the world's deadliest diseases.
For decades, scientists assumed the pancreatic ducts were simple, homogeneous structures. But Ph.D. researcher Jan-Lars Van den Bossche and his colleagues at the university's Translational Oncology Research Center, led by Professor Dr. Ilse Rooman, saw something different when they mapped healthy human pancreatic tissue at the cellular level using advanced imaging technology. The ducts, they discovered, have a layered architecture—and nested within those layers are specific cell types that nobody expected to find outside of tumors.
The revelation matters because pancreatic cancer remains stubbornly lethal. It is among the most aggressive human cancers and traditionally has been difficult to treat, partly because researchers never fully understood what separates healthy tissue from malignant growths. Most pancreatic tumors originate in the drainage ducts, yet the biological foundation for understanding different tumor variants has remained murky. By establishing what normal looks like at the cellular level, Rooman's team has created a baseline for spotting when things go wrong.
The study, published in the journal Gut, reveals something unexpected: those rare cells in healthy pancreases that resemble aggressive tumor cells might play a direct role in cancer development. This opens a new pathway for detection. "Understanding cancer starts with knowing about the healthy organ," Prof. Rooman explained. "Now that we know that these cells are already naturally present, we can start investigating whether they play a role in the development of the tumor. This may offer opportunities for early detection."
When the researchers compared their healthy-tissue findings against pancreatic cancer samples, stark contrasts emerged. In the most common variant, pancreatic ductal adenocarcinoma (PDAC), the original cellular organization was found to be completely destroyed. But in a rarer, far more aggressive form called adenosquamous carcinoma (ASCP), something remarkable occurred: the specific cell types and their precise spatial arrangement from the healthy pancreas were almost perfectly preserved.
This distinction carries profound clinical implications. Currently, patients with ASCP—despite its extreme aggressiveness—are treated identically to patients with the classical PDAC variant. The researchers argue this one-size-fits-all approach is outdated and ineffective. Because ASCP tumors retain the cellular architecture of healthy tissue, they present new opportunities for targeted intervention that would not work on PDAC tumors with their scrambled architecture.
The work represents a turning point in pancreatic cancer research, moving from broad generalizations to precision understanding. By mapping the cellular landscape of health, the Free University of Brussels team has created a more accurate roadmap for detecting and treating disease. In the coming years, this foundation may help doctors identify at-risk patients earlier and design therapies tailored to specific tumor variants—offering real hope in a field where hope has been scarce.